AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2501967
Drug: Subcutaneous infusion
RxNorm normalized name: subcutaneous infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infusion of GHRH (1-29)NH2 at doses of 5 and 10 micrograms/kg/hour
Trial: 2501967
Drug: Oral pyridostigmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pyridostigmine 60 mg
Trial: 367457
Drug: Agar (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agar (1 g/kg/day) orally in 4 daily doses from the 1st to the 5th day of life
Trial: 29308939
Drug: Kinesio Taping®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio Taping® (standard treatment plus application of Kinesio Taping® on the respiratory muscles)
Trial: 29308939
Drug: Control (medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (medication and standard physiotherapy treatment)
Trial: 27749236
Drug: Anti-TNF inhibitors
RxNorm normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF inhibitors
Trial: 23121563
Drug: Hb concentration
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hb concentration of 7·3 g dL(‐1) (restrictive group)
Trial: 23121563
Drug: Hb concentration
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hb concentration of 8·9 g dL(‐1) (liberal group)
Trial: 20354452
Drug: 6 mg/m
RxNorm normalized name: phenol 6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/m MMC on day 1 and 125 mg/m irinotecan on days 2 and 9 (arm A)
Trial: 20354452
Drug: 3 mg/m
RxNorm normalized name: urea 0.3 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/m MMC on days 1 and 8 and 125 mg/m irinotecan on days 2 and 9 (arm B)
Trial: 1918553
Drug: Thermal biofeedback
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal biofeedback (TBF) treatment with regular home practice (group 1)
Trial: 1918553
Drug: Thermal biofeedback
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal biofeedback (TBF) treatment without home practice (group 2)
Trial: 6233335
Drug: Isotretinoin 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin 1.0 mg/kg/day
Trial: 23110500
Drug: Diethylstilbestrol (DES)
RxNorm normalized name: Diethylstilbestrol
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (DES) 1-3 mg daily with 75 mg aspirin
Trial: 18837197
Drug: Electrical Twitch‐Obtaining
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical Twitch‐Obtaining Intramuscular Stimulation (eToims) using ET127 system, 3 Hz, 4 stimuli/site
Trial: 16247790
Drug: CHOP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP with 80 mg/day of valsartan
Trial: 1690068
Drug: Indoramin 20
RxNorm normalized name: indoramin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin 20 mg bd
Trial: 1690068
Drug: Indoramin 20
RxNorm normalized name: indoramin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin 20 mg nocte
Trial: 7084142
Drug: Diazepam solution
RxNorm normalized name: diazepam Oral Solution
DrugBank: Diazepam (DB00829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazepam solution 20 mg administered rectally
Trial: 25592561
Drug: Intensified post-operative
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified post-operative chemotherapy (SIOPWT2001)
Trial: 25592561
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control chemotherapy (SIOP93-01)
Trial: 25592561
Drug: Intensified treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified treatment in Stage I (SIOPWT2001)
Trial: 25592561
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control treatment in Stage I (SIOP93-01)
Trial: 20071596
Drug: ATV 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV 300 mg with ritonavir (RTV) 100 mg (ATV300/r, n = 95)
Trial: 20071596
Drug: ATV 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV 400 mg (ATV400; n = 105)
Trial: 15642080
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day added to simvastatin 20 mg/day
Trial: 15642080
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg/day (doubling the dose of simvastatin)
Trial: 12140204
Drug: Oral aldose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral aldose reductase inhibitor (ONO-2235)
Trial: 7006442
Drug: ICI 35868
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 35868 (Diprivan) 1-2 mg/kg
Trial: 7006442
Drug: Althesin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Althesin 0.5 ml/kg
Trial: 29716660
Drug: Blended psychosocial
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended psychosocial support program based on Acceptance and Commitment Therapy, consisting of 1 face-to-face contact, 6 online guided modules, and 1 telephone contact over 8 weeks.
Trial: 24415271
Drug: Zofenopril 30
RxNorm normalized name: zofenopril 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril 30 mg plus HCTZ 12.5 mg
Trial: 24415271
Drug: Irbesartan 150
RxNorm normalized name: irbesartan 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 150 mg plus HCTZ 12.5 mg
Trial: 22764601
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg/d, PO in the morning)
Trial: 15804294
Drug: Histamine concentrations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine concentrations (0.1, 1.0, and 10 mg/ml)
Trial: 12483236
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg CHX tablets
Trial: 12483236
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg CHX tablets
Trial: 2077497
Drug: meperidine 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 0.50 mg/lb
Trial: 2077497
Drug: meperidine 1.00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 1.00 mg/lb
Trial: 2077497
Drug: meperidine (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine (highest dose)
Trial: 31688449
Drug: Pooled antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pooled antagonist group (haloperidol, flupentixol, olanzapine)
Trial: 31688449
Drug: First-generation antipsychotics
RxNorm normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-generation antipsychotics (pooled)
Trial: 28890299
Drug: Fluticasone/formoterol (125/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone/formoterol (125/6 mcg BD)
Trial: 28890299
Drug: Budesonide/formoterol (200/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (200/6 mcg BD)
Trial: 17959530
Drug: Amikacin administration
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin administration at 3-4 h postburn (group A)
Trial: 17959530
Drug: Amikacin administration
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin administration at 10 h postburn (group B)
Trial: 17959530
Drug: Amikacin administration
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin administration at 20 h postburn (group C)
Trial: 17959530
Drug: Amikacin administration
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Amikacin administration at 30 h postburn (group D)
Trial: 11585103
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment guided by plasma levels of N-BNP
Trial: 11585103
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment based on clinical criteria
Trial: 9686773
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg efaroxan, given three times per day
Trial: 2685934
Drug: Interstitial Ir‐192
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interstitial Ir‐192 boost dose to the tumor bed immediately following resection
Trial: 30451147
Drug: Mediterranean lemonade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean lemonade (ML)
Trial: 25956954
Drug: Intramuscular phloroglucinol
RxNorm normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular phloroglucinol (80 mg)
Trial: 25956954
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (400 mg)
Trial: 21807831
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of COSP and CMHA services
Trial: 19523013
Drug: Lecozotan 0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecozotan 0.1, 0.25, 0.5, 1 and 5 mg q12h
Trial: 19523013
Drug: Lecozotan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecozotan 0.5 mg and 5 mg q12h
Trial: 19523013
Drug: Single-dose lecozotan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose lecozotan 2, 5 and 10 mg
Trial: 15608803
Drug: Age-specific insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Age-specific insulin resistance rates
Trial: 11763111
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pyridostigmine bromide (PB) every 8 hours for 13 doses
Trial: 11763111
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg pyridostigmine bromide (PB) every 8 hours for 13 doses
Trial: 9750974
Drug: Individual cognitive‐behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual cognitive‐behavior therapy (11 sessions)
Trial: 7995616
Drug: Intranasal (D‐Ser6)‐gonadotrophin‐releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (D‐Ser6)‐gonadotrophin‐releasing hormone (GnRH) analogue (buserelin) administered at a mean dose of 25 micrograms/kg/day for a mean period of 14 months
Trial: 24159562
Drug: Amiodarone (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (median dose 300 mg)
Trial: 11208684
Drug: Implantable cardioverter-defibrillator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable cardioverter-defibrillator therapy
Trial: 18481710
Drug: Xingnao Kaiqiao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnao Kaiqiao acupuncture (once each day, for 4 weeks) + routine treatment of western medicine
Trial: 18481710
Drug: Routine acupuncture
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine acupuncture + routine treatment of western medicine
Trial: 11967729
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (10-20 mg once daily)
Trial: 11967729
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (20-40 mg once daily)
Trial: 11967729
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (5-20 mg once daily)
Trial: 10101728
Drug: D-fenfluramine (D-FEN)
RxNorm normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-fenfluramine (D-FEN) 30 mg PO
Trial: 758705
Drug: Standard postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard postoperative fluid therapy (Control)
Trial: 31888626
Drug: Intravenous C1‐INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous C1‐INH (50 IU/kg)
Trial: 31888626
Drug: Intravenous C1‐INH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous C1‐INH
Trial: 29458749
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg ferric carboxymaltose (FCM)
Trial: 22810740
Drug: Preventive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive therapy with pantogam at a mean dose of 1.8 g/daily
Trial: 22810740
Drug: Cessation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation therapy with pantogam at a mean dose of 1.2 g/daily
Trial: 17697863
Drug: Alpha-linolenic acid
RxNorm normalized name: Alpha-linolenic Acid
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-linolenic acid (ALA) supplementation via flaxseed oil capsules (increasing ALA to 5% of total energy intake) for 8 weeks.
Trial: 16224843
Drug: Intra-operative (Iop)
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-operative (Iop) group received 0.5 mg/kg pethidine intravenously at the time of fascia closure
Trial: 16224843
Drug: Post-operative (Pop)
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative (Pop) group received 0.5 mg/kg pethidine intravenously on arrival in the post‐anaesthesia care unit
Trial: 7789662
Drug: Oral sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sensorimotor therapy for 10 weeks
Trial: 7789662
Drug: Oral sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sensorimotor therapy for 20 weeks
Trial: 7789662
Drug: Oral sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sensorimotor therapy (10 and 20 weeks)
Trial: 31856903
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) plus behavioral experiments (BEs)
Trial: 31856903
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) as usual
Trial: 25891115
Drug: LCPUFA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPUFA supplementation (DHA 300 mg/day, EPA 100 mg/day, ARA 120 mg/day)
Trial: 21248159
Drug: Parenteral challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral challenge with MACP
Trial: 11874551
Drug: 10% Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Intralipid (2 kcal min(‐1)) - Continuous infusion (CID)
Trial: 11874551
Drug: 10% Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Intralipid (2 kcal min(‐1)) - Pulsatile infusion (PID)
Trial: 10798029
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no handwashing agent mentioned)
Trial: 8926741
Drug: Intravenous cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cocaine (25 mg, cocaine HCl)
Trial: 8926741
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine (32 mg, cocaine HCl)
Trial: 8926741
Drug: Smoked cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cocaine (42 mg, cocaine base)
Trial: 7009440
Drug: Aminophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (6 mg/kg i.v.)
Trial: 7009440
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 mcg per inhalationem)
Trial: 27246705
Drug: Status quo
RxNorm normalized name: Statuss Green Reformulated Jan 2012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Status quo (zinc and ORS co-administered without bundling)
Trial: 18300441
Drug: Compound betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compound betamethasone injection (1 ml, postaural, single injection)
Trial: 12151964
Drug: Oxaliplatin 130
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 130 mg/m2 on day 1 and daily oral UFT 350 mg/m2 in 3 divided doses for 21 days, repeated every 21 days
Trial: 3290517
Drug: Acyclovir 400
RxNorm normalized name: acyclovir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 400 mg orally twice daily (suppressive treatment)
Trial: 3290517
Drug: Placebo (episodic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (episodic treatment)
Trial: 3290517
Drug: Acyclovir (suppressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (suppressive therapy)
Trial: 3290517
Drug: Acyclovir (episodic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir (episodic therapy)
Trial: 28027810
Drug: IPV Vaccine
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPV Vaccine SSI
Trial: 17554786
Drug: Cisplatin (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (7 mg/kg administered intraperitoneally on Days 0 and 21)
Trial: 15008338
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of air abrasion and phosphoric acid etching
Trial: 10764336
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine (analgesia group)
Trial: 8354027
Drug: Caffeine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (250 mg intravenously)
Trial: 8354027
Drug: Nicotine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (4 mg chewing gum)
Trial: 8354027
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of caffeine and nicotine
Trial: 2941966
Drug: 5'‐dFUrd 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'‐dFUrd 5 g/m2 as a 1‐h infusion for 5 days in 3 cycles at intervals of 4 weeks
Trial: 2941966
Drug: 5'‐dFUrd 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'‐dFUrd 3 g/m2 as a 1‐h infusion for 5 days in 3 cycles at intervals of 4 weeks
Trial: 2941966
Drug: High-risk group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk group (cachectic patients and patients with a pathological EEG before treatment)
Trial: 31259807
Drug: Ocriplasmin (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocriplasmin (0.125 mg)
Trial: 27727279
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single ultra-low dose of aldesleukin (0.101 × 106 IU/m2)
Trial: 27727279
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single ultra-low dose of aldesleukin (0.497 × 106 IU/m2)
Trial: 27727279
Drug: Lowest doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest doses of aldesleukin (0.040 × 106 and 0.045 × 106 IU/m2)
Trial: 27727279
Drug: A single
RxNorm normalized name: Hemoccult Sensa Single Slide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single ultra-low dose of aldesleukin
Trial: 22129171
Drug: Dipyridamole 200
RxNorm normalized name: dipyridamole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole 200 mg slow release twice daily
Trial: 21374068
Drug: Arzoxifene 20
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arzoxifene 20 mg/day
Trial: 12954577
Drug: Arzoxifene 50
RxNorm normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arzoxifene 50 mg/day
Trial: 10983645
Drug: CSF drug
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CSF drug concentrations of RTV and SQV
Trial: 8243699
Drug: Pharmacologic technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacologic technique (diluted vasopressin 20 U in 20 mL normal saline)
Trial: 29426774
Drug: Ciprofloxacin 20
RxNorm normalized name: ciprofloxacin 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 20 mg/kg/day
Trial: 27416541
Drug: G5K solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G5K solution
Trial: 27416541
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Ringer's maleate solution)
Trial: 26054178
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group (zinc lactate and magnolia bark extract tablets)
Trial: 6357269
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo tablets)